KR100694667B1 - 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 - Google Patents

생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 Download PDF

Info

Publication number
KR100694667B1
KR100694667B1 KR1019990055802A KR19990055802A KR100694667B1 KR 100694667 B1 KR100694667 B1 KR 100694667B1 KR 1019990055802 A KR1019990055802 A KR 1019990055802A KR 19990055802 A KR19990055802 A KR 19990055802A KR 100694667 B1 KR100694667 B1 KR 100694667B1
Authority
KR
South Korea
Prior art keywords
itraconazole
spray drying
solubility
spray
absorption
Prior art date
Application number
KR1019990055802A
Other languages
English (en)
Korean (ko)
Other versions
KR20010054823A (ko
Inventor
권종원
김정훈
왕훈식
장선우
배웅탁
Original Assignee
동아제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아제약주식회사 filed Critical 동아제약주식회사
Priority to KR1019990055802A priority Critical patent/KR100694667B1/ko
Priority to CN99817076A priority patent/CN1398184A/zh
Priority to PCT/KR1999/000854 priority patent/WO2001041765A1/en
Priority to AU18964/00A priority patent/AU1896400A/en
Priority to CA002393737A priority patent/CA2393737A1/en
Priority to JP2001543110A priority patent/JP2003516354A/ja
Priority to EP99962555A priority patent/EP1274432A4/en
Publication of KR20010054823A publication Critical patent/KR20010054823A/ko
Application granted granted Critical
Publication of KR100694667B1 publication Critical patent/KR100694667B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1019990055802A 1999-12-08 1999-12-08 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 KR100694667B1 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1019990055802A KR100694667B1 (ko) 1999-12-08 1999-12-08 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
CN99817076A CN1398184A (zh) 1999-12-08 1999-12-31 具有改善的生物利用度和缩小的个体内和个体间吸收差异的含有伊曲康唑的组合物
PCT/KR1999/000854 WO2001041765A1 (en) 1999-12-08 1999-12-31 Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption
AU18964/00A AU1896400A (en) 1999-12-08 1999-12-31 Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption
CA002393737A CA2393737A1 (en) 1999-12-08 1999-12-31 Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption
JP2001543110A JP2003516354A (ja) 1999-12-08 1999-12-31 生物学的利用率が向上し、個人間及び個人内の吸収偏差が狭められたイトラコナゾール含有組成物
EP99962555A EP1274432A4 (en) 1999-12-08 1999-12-31 COMPOSITIONS CONTAINING ITRACONAZOLE WITH IMPROVED BIOAVAILABILITY AND LOW INTRA-INDIVIDUAL AND INTER-INDIVIDUAL GAP OF ITS ABSORPTION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990055802A KR100694667B1 (ko) 1999-12-08 1999-12-08 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제

Publications (2)

Publication Number Publication Date
KR20010054823A KR20010054823A (ko) 2001-07-02
KR100694667B1 true KR100694667B1 (ko) 2007-03-14

Family

ID=19624262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990055802A KR100694667B1 (ko) 1999-12-08 1999-12-08 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제

Country Status (7)

Country Link
EP (1) EP1274432A4 (zh)
JP (1) JP2003516354A (zh)
KR (1) KR100694667B1 (zh)
CN (1) CN1398184A (zh)
AU (1) AU1896400A (zh)
CA (1) CA2393737A1 (zh)
WO (1) WO2001041765A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
KR100432949B1 (ko) * 2000-06-13 2004-05-31 코오롱제약주식회사 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
KR100441745B1 (ko) * 2001-11-30 2004-07-27 환인제약 주식회사 이트라코나졸의 경구투여용 조성물과 그 제조방법
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
BR0307344A (pt) 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
KR100557680B1 (ko) * 2002-11-23 2006-03-07 한국유나이티드제약 주식회사 이트라코나졸의 용해도 개선을 위한 펠렛제제 및 그제조방법
PT1438961E (pt) † 2003-01-14 2007-05-31 Cimex Pharma Ag Composição bioquivalente de itraconazol disperso num polímero hidrofílico.
PT1438960E (pt) † 2003-01-14 2007-06-19 Cimex Pharma Ag Composição de itraconazole disperso num polímero hidrofílico possuindo biodisponibilidade melhorada
HU227142B1 (en) * 2003-07-02 2010-08-30 Egis Gyogyszergyar Nyilvanosan Capsule of improved release containing fluconazole
EP1653927B1 (en) 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
CN1285590C (zh) * 2004-02-23 2006-11-22 上海医药工业研究院 伊曲康唑盐酸盐口服固体组合物和制备方法
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
KR100555794B1 (ko) * 2005-03-17 2006-03-03 삼천당제약주식회사 이트라코나졸을 함유하는 경구용 조성물
EP2004150A1 (en) * 2006-03-27 2008-12-24 Panacea Biotec Ltd. Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
CN102458373A (zh) * 2009-05-27 2012-05-16 株式会社三养生物制药 生物利用度提高的包含难溶性药物的微球及其制备方法
CN102309488A (zh) * 2010-07-02 2012-01-11 北京京卫燕康药物研究所有限公司 一种伊曲康唑药物组合物及其制备方法
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633015A (en) * 1992-09-03 1997-05-27 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer
WO1998000116A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Oral composition comprising a triazole antifungal compound
KR19990055802A (ko) * 1997-12-27 1999-07-15 김영환 반도체소자 제조방법
KR19990062448A (ko) * 1997-12-31 1999-07-26 이병언 이트라코나졸 경구용 제제 및 그의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
AU1511399A (en) * 1997-12-31 1999-07-19 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
NZ511792A (en) * 1998-11-20 2003-08-29 Skyepharma Canada Inc Dispersible phospholipid stabilized microparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633015A (en) * 1992-09-03 1997-05-27 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer
WO1998000116A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Oral composition comprising a triazole antifungal compound
KR19990055802A (ko) * 1997-12-27 1999-07-15 김영환 반도체소자 제조방법
KR19990062448A (ko) * 1997-12-31 1999-07-26 이병언 이트라코나졸 경구용 제제 및 그의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1019990055802 - 632585

Also Published As

Publication number Publication date
EP1274432A1 (en) 2003-01-15
WO2001041765A1 (en) 2001-06-14
JP2003516354A (ja) 2003-05-13
AU1896400A (en) 2001-06-18
EP1274432A4 (en) 2004-11-10
KR20010054823A (ko) 2001-07-02
CN1398184A (zh) 2003-02-19
CA2393737A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
KR100694667B1 (ko) 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
JP7211644B2 (ja) ニロチニブの医薬組成物
TWI389691B (zh) 可口服且具有活性成分快速釋出之固態醫藥劑型
JP4334869B2 (ja) 溶解性または経口吸収性の改善された組成物
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
KR101352130B1 (ko) 디클로페낙 제제 및 이용 방법
AU2016372683A1 (en) Complexes of celecoxib and its salts and derivatives process for the preparation thereof and pharmaceutical compositions containing them
US20090017122A1 (en) Drug Forms Having Controlled Bioavailability
Strojewski et al. Kollidon® VA 64 and Soluplus® as modern polymeric carriers for amorphous solid dispersions
US20080206348A1 (en) Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers
CA2612288A1 (en) Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
KR101441450B1 (ko) 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
KR20010097244A (ko) 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
KR102306856B1 (ko) 용출률 및 경구 흡수율이 개선된 셀레콕시브 고체 분산체 및 이의 제조방법
KR102363727B1 (ko) 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
EP2520300A1 (en) Pharmaceutical composition for oral administration
EP2540281A1 (en) Solid self-microemulsifying systems
WO1999020277A1 (fr) Composition medicamenteuse a dissolution rapide
WO2023244684A1 (en) Formulations of 2-arylbenzimidazole compounds
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
TW202416960A (zh) 2-芳基苯并咪唑化合物之調配物
JP2023547736A (ja) メロキシカム含有医薬組成物
KR100441745B1 (ko) 이트라코나졸의 경구투여용 조성물과 그 제조방법
KR100432949B1 (ko) 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법
KR100708974B1 (ko) 수용성 수지를 이용한 이트라코나졸 고체분산체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121231

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20131226

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20141211

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20161222

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20171219

Year of fee payment: 12